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Abstract
Background: Mutations in the neurofibromatosis type 2 (NF2) tumor-suppressor gene have been identified in not only NF2-
related tumors but also sporadic vestibular schwannomas (VS). This study investigated the genetic and epigenetic
alterations in tumors and blood from 30 Korean patients with sporadic VS and correlated these alterations with tumor
behavior.
Methodology/Principal Findings: NF2 gene mutations were detected using PCR and direct DNA sequencing and three
highly polymorphic microsatellite DNA markers were used to assess the loss of heterozygosity (LOH) from chromosome 22.
Aberrant hypermethylation of the CpG island of the NF2 gene was also analyzed. The tumor size, the clinical growth index,
and the proliferative activity assessed using the Ki-67 labeling index were evaluated. We found 18 mutations in 16 cases of
30 schwannomas (53%). The mutations included eight frameshift mutations, seven nonsense mutations, one in-frame
deletion, one splicing donor site, and one missense mutation. Nine patients (30%) showed allelic loss. No patient had
aberrant hypermethylation of the NF2 gene and correlation between NF2 genetic alterations and tumor behavior was not
observed in this study.
Conclusions/Significance: The molecular genetic changes in sporadic VS identified here included mutations and allelic loss,
but no aberrant hypermethylation of the NF2 gene was detected. In addition, no clear genotype/phenotype correlation was
identified. Therefore, it is likely that other factors contribute to tumor formation and growth.
Citation: Lee JD, Kwon TJ, Kim U-K, Lee W-S (2012) Genetic and Epigenetic Alterations of the NF2 Gene in Sporadic Vestibular Schwannomas. PLoS ONE 7(1):
e30418. doi:10.1371/journal.pone.0030418
Editor: Sumitra Deb, Virginia Commonwealth University, United States of America
Received August 29, 2011; Accepted December 15, 2011; Published January 25, 2012
Copyright:  2012 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a grant from the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A100367).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kimuk@knu.ac.kr
. These authors contributed equally to this work
Introduction
Vestibular schwannomas (VS) are benign tumors of the neural
sheath that originate on the vestibular nerves. They occur as either
sporadic unilateral tumors or bilateral tumors that are a
manifestation of neurofibromatosis type 2 (NF2). The loss of both
wild-type copies of the NF2 tumor suppressor gene is common in
the pathogenesis of both sporadic and NF2-related schwannomas
[1,2]. Although mutations in the NF2 gene have been reported in
53,70% of sporadic VS (Neff et al., 2006), genetic alterations
alone cannot explain the gene inactivation.
Recently, the importance of DNA methylation in tumors has
been acknowledged, and the hypermethylation of promoter-
associated CpG islands is emerging as the primary mechanism
of epigenetic inactivation of tumor-suppressor genes in cancer
development [3,4]. Therefore, hypermethylation in the regulatory
region of the NF2 gene has been suggested as a possible
mechanism of gene inactivation [5].
Attempts have been made to correlate the clinical expression of
the sporadic VS tumors with specific NF2 mutations [6,7,8]. Given
the heterogeneity of the clinical response to various types of
mutations, no clear genotype/phenotype correlation has been
established [9]. However, a recent study reported a significant
relationship between tumor behavior and genetic alteration in
Chinese patients [6].
The present study analyzed the genetic alterations in sporadic
VS, including mutations, loss of heterozygosity (LOH), and
epigenetic alterations of the NF2 gene, and correlated these
alterations with tumor behavior in Korean patients.
Materials and Methods
Patients
A total of 30 unrelated subjects with sporadic unilateral VS were
recruited from the Department of Otorhinolaryngology - Head
and Neck Surgery, Soonchunhyang University Bucheon Hospital
and the Department of Otorhinolaryngology, Yonsei University
Health System Hospital, Korea. The subjects included 10 males
and 20 females ranging in age from 11 to 73 years (mean age, 48.3
years). Blood was collected from all patients, and tumor tissue was
obtained at the time of surgery and stored at 280uC before DNA
isolation. DNA was isolated from both peripheral blood leukocytes
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investigate NF2 germ-line mutations and tumor tissue DNA was
examined for somatic mutations of NF2. Written informed consent
was obtained from all patients, and the study was approved by the
ethics committee of Soonchunhyang University Hospital.
Tumor behavior
Tumor behavior was assessed using tumor size (maximum
diameter in centimeters), a clinical growth index, and proliferative
activity according to the Ki-67 labeling index (LI). The clinical
growth index was calculated by dividing the tumor size (maximum
diameter) by the duration of the initial presenting symptom in
years. To determine the Ki-67 LI, immunohistochemistry was
performed on formalin-fixed paraffin sections of the VS using an
anti-MIB-1 antibody followed by microscopy (Olympus, Tokyo,
Japan); all nuclear-stained tumor cells were counted at 4006
magnification. The mean LI was determined as the number of
positively stained nuclei in three randomly chosen fields divided by
the total number of cells in the selected areas. The results are
expressed as the percentage of the total cell number.
Mutational analysis
For the 30 subjects, genomic DNA was isolated from peripheral
blood using a FlexiGene DNA extraction kit (QIAGEN, Hilden,
Germany) and from the tumor tissue using a Puregene Buccal Cell
Core Kit B (QIAGEN). For the blood and tumor DNA samples,
the entire coding region (exon 1–16) and exon-intron boundaries
of the NF2 gene were amplified by polymerase chain reaction
(PCR) using appropriate primer sets. PCR was performed in 25-ml
reactions containing 0.2 mM of each dNTP, 10 mM forward and
reverse primers, 106Taq buffer, 0.25 U of Taq DNA polymerase
(Solgent, Daejeon, Korea), and 25 ng of genomic DNA from the
blood or tumor, respectively. The PCR conditions consisted of an
initial denaturation at 95uC for 15 min, followed by 30 cycles of
95uC for 20 s, 57uC for 40 s, and 72uC for 1 min, with a final 5-
min extension at 72uC. The PCR products were confirmed by
electrophoresis in 2% agarose gels stained with ethidium bromide
(EtBr). For each PCR product, 7 ml were treated with 0.1 U of
shrimp alkaline phosphatase (USB, Cleveland, OH, USA) and 1 U
of exonuclease I (USB) at 37uC for 1 h, followed by incubation at
80uC for 15 min for enzyme inactivation. The purified PCR
products were sequenced in 10-ml reactions containing 5 mM
primer, 0.2 ml of ABI Big Dye Terminator v3.1 Cycle Sequencing
Kit reagent (Applied Biosystems, Foster City, CA, USA), and 1 ml
of 56 buffer. The PCR conditions consisted of 2 min at 95uC,
followed by 30 cycles of 95uC for 20 s, 55uC for 20 s, and 60uC for
4 min. The sequencing reaction products were ethanol precipi-
tated, and the pellets were resuspended in 10 ml of HiDi-
formamide loading dye. An ABI 3130XL DNA sequencer was
used to resolve the products, and the data were analyzed using
ABI Sequencing Analysis (v5.0) and SeqScape software (v2.5). The
resultant sequence was compared with the NF2 sequence in
GenBank (GenBank ID NM_016418).
Loss of heterozygosity assay
Loss of heterozygosity (LOH) was determined using flanking
and intragenic microsatellite markers in the NF2 region of
chromosome 22. Three microsatellite markers were chosen for
the NF2 gene region from the NCBI database (www.ncbi.nlm.nih.
gov): D22S275 is centromeric, D22S929 is intragenic within intron
1 of the NF2 gene, and D22S268 is telomeric to the NF2 gene.
These three microsatellite markers are tightly linked to the NF2
gene (mean distance between D22S275 and D22S268 is 0.7 Mb).
PCR was performed to genotype the samples, and fluorescently
labeled (FAM) markers were used. Each 10-ml reaction contained
0.2 mM of each dNTP, 10 mM labeled forward and reverse
primers, 106Taq buffer, 0.25 U Taq DNA polymerase (Solgent),
and 25 ng of blood genomic DNA or tumor DNA. The PCR
conditions consisted of an initial 2 min at 95uC, 35 cycles of 95uC
for 20 s, 57uC for 40 s, and 72uC for 30 s, and a final extension at
72uC for 5 min. Subsequently, each PCR product was diluted with
distilled water. HiDi-formamide and the GeneScan
TM 500 LIZH
size standard (Applied Biosystems) were added to the diluted PCR
products, and the samples were loaded (30 cm capillary, POP 7
polymer) in an ABI 3130XL genetic analyzer. The genotypes of
the microsatellite markers were analyzed using GeneMapper
software (v3.7).
Methylation-specific PCR (MSP)
Abnormal DNA methylation, i.e., hypermethylation, in the
promoter region, including the CpG island, of the NF2 gene was
examined using bisulfate modification of tumor tissue genomic
DNA from all the patients. The bisulfate modification process was
performed using an EZ-96 DNA methylation kit (Zymo Research,
Orange, CA, USA). Bisulfate converts unmethylated cytosines in
DNA into uracil, while methylated cytosines remain unchanged;
uracil is then converted into thymidine in the subsequent PCR
amplification. To test for methylation, methylation-specific PCR
(MSP) was performed using a methylation-specific primer pair
(forward 59-GAGTTATTTTAAAGGAGGCGGGAC-39 and re-
verse 59-GAAACCCCTAAACGACAAC-GAC-39; 304-bp prod-
uct), and unmethylation-specific PCR was performed using an
unmethylation-specific primer pair (forward 59-AGTTATTT-
TAAAGGAGGTGGGATGG-39 and reverse 59-AAACAAA-
ACCCCTAAACAACAA-39; 307-bp product). The primers were
designed using the MethPrimer program available at http://www.
urogene.org/methprimer/index1.html [10]. Normal genomic
DNA was used as the negative control in the MSP, and normal
genomic DNA that was methylated using CpG methylase M.Sss1
(New England Biolabs, Beverly, MA) was used as the positive
control. The PCR conditions consisted of an initial 5 min at 95uC,
35 cycles of 95uC for 20 s, 57uC for 40 s, and 72uC for 1 min, and
a final extension at 72uC for 5 min. The PCR products were
confirmed by 2% agarose gel electrophoresis and EtBr staining.
Statistical analysis
Statistical analysis was performed using the SPSS 18.0 statistics
software for Windows (SPSS, Chicago, IL). Student’s t-test was
used to compare the tumor size, clinical growth index, and Ki-67
LI between the patients with and without mutations. P-values less
than 0.05 were considered significant.
Results
Mutational analysis of the NF2 gene
Mutational analysis of the entire coding region, i.e., exons 1 to
16, and the flanking intronic sequences of the NF2 gene was
performed using direct sequencing using genomic DNA from the
blood and tumors of 30 patients with VS. No germ-line mutations
were found in blood DNA, whereas 18 mutations were found in
tissue DNA. These mutations included frameshift, nonsense, in-
frame, missense, and splice site mutations. Nine different
mutations (five single-nucleotide deletions or insertions, two
multiple-nucleotide deletions in the coding region, and two several
nucleotide deletions in the coding region and flanking intron
sequences) were identified. Six of the eight frameshift mutations
resulted in the premature termination of translation and the other
two frameshift mutations generated a truncated protein via exon
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78 bp deletion mutation led to an in-frame deletion. In addition,
seven nonsense mutations were identified that caused the
generation of a prematurely terminated protein due to an early
stop codon. Among the patients, two (cases 4 and 24) had two
different mutations each. One patient had a missense mutation of
a thymine to guanine transition at nucleotide 136 in exon 2,
causing an amino acid change from leucine to arginine. One
patient had a splice site mutation at a donor site, and the splice site
mutation led to a substitution of guanine for adenine (GT to AT)
at the donor site in intron 3, thus causing an in-frame mutation by
skipping exon 3. Consequently, all of the mutations in patients
with VS were somatic mutations of the NF2 gene.
Loss of heterozygosity
Genomic DNA (blood and tumor DNA) from all 30 patients
was investigated for LOH using three highly polymorphic
microsatellite markers near the NF2 gene region: two flanking
markers (D22S268 and D22S275) and one intragenic marker
within intron 1 (D22S929). Comparative analysis of the LOH of
genomic DNA from blood and tumor samples showed heterozy-
gous blood DNA and homozygous tumor DNA (Fig. 1). Of the 30
patients with VS, 9 (30%) had LOH, and 8 of the 9 showed LOH
with the flanking marker D22S268 and the intragenic marker
D22S929. Every patient with LOH had the D22S275 flanking
marker. Thus, 21 of the 30 patients (70%) did not show LOH in
their tumor DNA (Table 1).
CpG island hypermethylation of the NF2 gene
Methylation and unmethylation primers were designed for the
region approximately 350 bp to 650 bp upstream of the start
codon, which includes the CpG island, using the program
MethPrimer (Li and Dahiya, 2002). The methylation state of the
promoter region was examined using MSP and unmethylation-
specific PCR (USP). The promoter region of the bisulfite-treated
DNA of all patients and the negative control (NC) was amplified
using USP, and the PCR products were identified using
electrophoresis. The bisulfite-treated DNA positive control (PC)
was amplified using only MSP. The results demonstrated that the
expression of the NF2 gene in all of the VS patients was not
repressed by hypermethylation of the promoter region.
Genetic alterations and tumor behavior
The average tumor sizes in the patients with mutations or LOH
and patients without mutations and LOH were 16.11 and
20.83 cm, respectively. The average clinical growth index (CGI)
values were 13.22 and 12.92, and the average Ki-67 labeling index
(LI) values were 2.21 and 2.54, respectively. There was no
significant difference in tumor size (p=0.105), CGI (p=0.878), or
Ki-67 LI (p=0.372) between the patients with mutations or LOH
and the patients without mutations and LOH. Thus, there was no
correlation between the nature of the NF2 gene mutation,
including LOH, and tumor behavior.
Discussion
This study investigated the genetic alterations in sporadic VS,
including mutations, loss of heterozygosity (LOH), and epigenetic
alterations of the NF2 gene, and compared these alterations with
the tumor behavior. The NF2 gene is frequently mutated in NF2-
related vestibular schwannomas [1,2], and mutations in this gene
have also been found in sporadic unilateral schwannomas
[8,11,12]. The rate of mutations is higher in unilateral
schwannomas than in familial schwannomas. We found 18 genetic
alterations (60%) in 30 Korean patients with sporadic VS, which
was in agreement with the 53–70% detection rate reported in
previous studies [9].
The majority of the mutations (88%) in our study were protein-
truncating mutations such as frameshift or nonsense mutations.
Among constitutional NF2 mutations, nonsense mutations are
significantly more common than frameshift mutations in NF2
patients, whereas frameshift mutations are significantly more
common than nonsense mutations among somatic NF2 mutations
in sporadic vestibular schwannomas [13]. We also found that
Figure 1. Loss of heterozygosity analysis of case No.1. A comparison of lymphocyte DNA and tumor DNA using the flanking, D22S268 and
D22S275, and intragenic, D22S929, microsatellite markers in the NF2 gene region. In case, three markers showed loss of heterozygosity by allele loss
in the tumor DNA.
doi:10.1371/journal.pone.0030418.g001
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mutations (35%) [14] . Donor splice site mutations and missense
mutations were rare, which was consistent with other studies
[7,8]. According to Knudson’s two-hit hypothesis [15], functional
inactivation of a specific tumor-suppressor gene requires two
separate genetic hits in the same gene in the same cell. For a
sporadic tumor, the probability of both mutations occurring in
the same cell is extremely small [16]. Two patients (cases 4 and
24) each had two different mutations that inactivated the NF2
gene. It is possible that LOH represents the second hit on the
remaining allele. Nine patients (30%) in our study had
chromosome 22 LOH, and seven patients had both LOH and
mutations. In our study, nine patients (30%) had two hits, and
another nine patients (30%) had only one hit (mutation or LOH).
It has been shown that mitotic recombination plays a role in the
occurrence of LOH, even though the rate of mitotic recombi-
nation is relatively low in sporadic VS compared to NF2-related
schwannomas [17]. In the other cases, we postulate that other
mechanisms, such as different genetic abnormalities or epigenetic
factors, were involved in the pathogenesis of the vestibular
schwannomas.
To search for other genes associated with vestibular schwanno-
ma tumorigenesis, Welling et al. [18] used cDNA microarray
analysis to evaluate gene expression profiles. They identified a
number of dysregulated genes involved in cell signaling, cell
division, and angiogenesis. Caye-Thomasen et al. [19] examined
the gene expression profile in vestibular schwannomas using a
microarray chip and identified 78 dysregulated genes involved in
the cell cycle, morphogenesis, development, adhesion, differenti-
ation, death, extracellular matrix, and protein binding.
Methylation of the promoter-associated CpG island is a possible
mechanism of tumor-suppressor gene inactivation in a variety of
human tumors [4]. Lomas et al. [20] proposed that aberrant NF2
hypermethylation may participate in the development of a
significant proportion of sporadic meningiomas. However, Kullar
et al. [21] recently reported that hypermethylation of the CpG
island of the NF2 gene was rare in sporadic vestibular
schwannomas. None of our patients showed repressed expression
of the NF2 gene due to hypermethylation of the promoter region.
Instead, methylation of other tumor-related genes may have
played a role in the development of these vestibular schwannomas
[22].
Several studies have examined whether genotype predicts the
disease severity [23]. Irving et al. [7] found no correlation between
the nature of the NF2 gene mutation and tumor behavior.
Conversely, Bian et al. [6] reported a significant relationship
between tumor behavior and genetic alterations in Chinese
patients. Consequently, we investigated whether there was a racial
difference in the genotype-phenotype correlation in sporadic
vestibular schwannomas. To quantify tumor behavior, the
previously mentioned studies used the clinical growth index
(CGI). However, the clinical growth index is far from ideal because
of the variability of the clinical symptoms and the uncertainty of
their duration. Therefore, we used tumor size and CGI as a
measure of tumor behavior. In the present study, we found no
difference in tumor behavior between Korean patients with and
without NF2 genetic alterations, suggesting that there is no racial
difference.
In summary, the present study found 16 cases of mutations and
9 cases of LOH in the NF2 genes of 30 Korean patients with
sporadic VS. However, no aberrant hypermethylation of the NF2
gene was detected, and no clear genotype/phenotype correlation
was identified in our study. Therefore, other factors are likely to
contribute to tumor formation and growth.
Table 1. Loss of heterozygosity (LOH) and mutation in sporadic vestibular schwannomas.
No Exon DNA sequence alteration Codon change Consequence LOH
D22S268 D22S275 D22S929
1 2 c.136T.G (p.L46R) 46 Missense +++
2 3 c.363+1G.A - Splicing donor site +++
3- - - - +++
4 2, 3 c.232_233 ins G c.303T.A
(p.Y101X)
78 101 Frameshift, Nonsense
6 3 c.280 del T 94 Frameshift +++
8 2 c.122G.A (p.W41X) 41 Nonsense
10 13 c.1379 del T 460 Frameshift
12 2 c.169C.T (p.R57X) 57 Nonsense +++
13 12 c.133 C.G (p.S444X) 444 Nonsense +++
14 - - - - +++
15 2 c.154_175del22 51–59 Frameshift
17 10 c.955C.T (p.Q319X) 319 Nonsense
21 10 c.963_964 ins A 322 Frameshift +
22 14 c.1568_1574+7del14 523–525+intron7bp Frameshift
24 7, 8 c.616G.T (p.E206X)
c.694_771del78
206 232–257 Nonsense In-frame deletion
27 4 c.364-8_408del53 Intron8bp+122–136 Frameshift
29 2 c.169C.T (p.R57X) 57 Nonsense
30 4 c.394 delT 132 Frameshift +++
doi:10.1371/journal.pone.0030418.t001
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